TELIX PHARMACEUTICALS LIMITED (TLX)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:

TLX - TELIX PHARMACEUTICALS LIMITED
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.15
Index: ASX200 | ASX300 | ALL-ORDS
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$9.86
06 Dec |
OPEN $9.75 |
HIGH $9.93 |
800,212 LOW $9.61 |
TARGET | |||||
|
OTHER COMPANIES IN THE SAME SECTOR | |||
1AD . ACR . ACW . ADO . AFP . AGH . ANP . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MXC . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PNV . PXS . PYC . RAC . RCE . RNO . SPL . TRP . VIT . ZNO . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY21 Actual |
FY22 Actual |
FY23 Forecast |
FY24 Forecast |
---|---|---|---|---|
EPS (cps) | xxx | - 33.5 | 21.9 | xxx |
DPS (cps) | xxx | 0.0 | 0.0 | xxx |
EPS Growth | xxx | N/A | N/A | xxx |
DPS Growth | xxx | N/A | N/A | xxx |
PE Ratio | xxx | N/A | 45.3 | xxx |
Dividend Yield | xxx | N/A | 0.0% | xxx |
Div Pay Ratio(%) | xxx | N/A | 0.0% | xxx |
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | -33.5 |
DPS All | xxx | xxx | xxx | xxx | 0.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | 160.1 M |
Book Value Per Share | xxx | xxx | xxx | xxx | 25.3 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | -64.0 M |
Net Profit Margin | xxx | xxx | xxx | xxx | -65.01 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | -253.34 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | -221.73 % |
Return on Assets | xxx | xxx | xxx | xxx | -56.20 % |
Return on Equity | xxx | xxx | xxx | xxx | -253.34 % |
Return on Total Capital | xxx | xxx | xxx | xxx | -153.82 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | -71.0 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | 1 M |
Long Term Debt | xxx | xxx | xxx | xxx | 10 M |
Total Debt | xxx | xxx | xxx | xxx | 10 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | 6 M |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | 116 M |
Price To Book Value | xxx | xxx | xxx | xxx | 28.75 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | 13.9 M |
Capex % of Sales | xxx | xxx | xxx | xxx | 8.66 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | 131 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | 103 M |
Research & Development | xxx | xxx | xxx | xxx | 58 M |
Investments - Total | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
TLX STOCK CHART

FNArena News on TLX
1 |
Australian Broker Call *Extra* Edition – Nov 28, 2023Nov 28 2023 - Daily Market Reports |
2 |
Rudi’s View: Outlook 2024, Is History Our Guide?Nov 08 2023 - Rudi's View |
3 |
Australian Broker Call *Extra* Edition – Oct 26, 2023Oct 26 2023 - Daily Market Reports |
4 |
Rudi’s View: Outlook Negative, With Plenty Of Silver LiningsSep 06 2023 - Rudi's View |
5 |
Australian Broker Call *Extra* Edition – Sep 04, 2023Sep 04 2023 - Daily Market Reports |
Latest Pharmaceuticals & Biotech/Lifesciences News
1 |
Dr Boreham’s Crucible: PYC TherapeuticsNov 22 2023 - Small Caps |
2 |
Dr Boreham’s Crucible: Paradigm BiopharmaceuticalsNov 06 2023 - Small Caps |
3 |
Dr Boreham’s Crucible: Argenica TherapeuticsSep 28 2023 - Small Caps |
4 |
Dr Boreham’s Crucible: Cleo DiagnosticsAug 30 2023 - Small Caps |
5 |
Breaking Boundaries: Medical PsychedelicsAug 21 2023 - Small Caps |
6 |
Momentum Keeps Building For Avita MedicalAug 15 2023 - Small Caps |
7 |
Dr Boreham’s Crucible: IDT AustraliaAug 14 2023 - Small Caps |
8 |
Treasure Chest: Less Smooth Road Ahead For CSLAug 01 2023 - Treasure Chest |
9 |
Dr Boreham’s Crucible: Telix PharmaceuticalsJul 31 2023 - Small Caps |
10 |
Dr Boreham’s Crucible: Arovella TherapeuticsJul 17 2023 - Small Caps |